Navigation Links
Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
Date:7/30/2008

CAMBRIDGE, Mass., July 30 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,381,790 (the '790 patent) which protects the composition of matter for its PI-2301 peptide copolymer for the treatment of autoimmune diseases.

PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in relapsing remitting multiple sclerosis patients in early 2009.

"This patent represents an important component in the development of our intellectual property in peptide copolymers, including PI-2301," stated Thomas P. Mathers, President and CEO of Peptimmune. "The '790 patent protects what we believe may become a very important therapy for the treatment of multiple sclerosis and other autoimmune diseases."

PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 has been designed to be more efficacious and more convenient (weekly versus daily dosing) than Copaxone for the treatment of multiple sclerosis. PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in some diseases. In a Phase I single ascending dose, double blind placebo controlled randomized study, all doses of PI-2301 were safe and well tolerated, and no serious adverse events were observed. Pharmacodynamic assays demonstrated evidence of immune exposure consistent with the pharmacologic mechanism of action for PI-2301, and dose-dependent pharmacokinetics was observed.

PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and, in preclinical studies, has shown to be more potent and eff
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
2. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
3. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
4. Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Calif., July 31, 2014 Pharmacyclics, Inc. (the "Company") ... recent developments for the quarter ended June 30, 2014. ... June 30, 2014 Revenue Total revenue for the quarter ... million for the quarter ended June 30, 2013 primarily due ... million. Total revenue for the six months ...
(Date:7/31/2014)... , July 31, 2014   Auxilium Pharmaceuticals , ... specialty biopharmaceutical company, today announced that the Company will ... Thursday, August 7, 2014 before the opening of the ... conference call that day at 8:30 a.m. ET to ... 2014. The presentation slides to be used during the ...
(Date:7/31/2014)... -- Decision Resources Group is launching an extension of its ... include ChinaTrack; the new capabilities track the ... providing detailed brand-level share tracking and analytics. ChinaTrack also ... Other key capabilities of the new line extension: ... end-user surveys of healthcare facilities, ChinaTrack data is paired ...
Breaking Medicine Technology:Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2
(Date:8/1/2014)... “When insulation goes bad,” Clean Crawls says, “It ... newly released article entitled, “ 5 Signs That Your ... ,” Clean Crawls explains the need to replace insulation ... critters. , Get a free attic insulation or ... http://www.cleancrawl.com/contact . , If crawl space or attic insulation ...
(Date:8/1/2014)... 2014 Over 20,000 entrepreneurs from around ... 2014 Market America | SHOP.COM International Convention at the ... annual event will introduce new products, technology, programs and ... and also feature a who’s who of celebrities. ... SHOP.COM Executive Team, successful entrepreneurs and celebrity guests. Previous ...
(Date:8/1/2014)... CA (PRWEB) August 01, 2014 ... advancing gynecologic endoscopic surgery, is pleased to announce ... in the United States and Europe, which strongly ... available to surgeons an endoscopic dry lab for ... of their endoscopic surgery skills. , Endoscopy is ...
(Date:8/1/2014)... 01, 2014 Stress management can be difficult ... hours of concentration and diminish rest and leisure time, stress ... is critical to find a way to manage stress in ... life. , “Having a good sense of work-life balance is ... Jacobs, founding clinician of SF Custom Chiropractic. “Stress, left ...
(Date:7/31/2014)... July 31, 2014 The 2013 ... developments about chemical listings, appellate decisions, litigation and ... may affect compliance with California's Proposition 65. , ... the law, regulations, history and trends impacting California's ... fourth installment of the series which adds approximately ...
Breaking Medicine News(10 mins):Health News:5 Signs That Insulation Should Be Replaced Detailed in a Newly Released Article By Clean Crawls 2Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 2Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 3Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 4Health News:Market America | SHOP.COM Set to Unveil Technology Enhancements and New Products at the 2014 International Convention 5Health News:AAGL Announces It Has Joined With Other Medical Societies to Encourage Hospitals Teaching Endoscopic Surgery to Establish Simulator Labs for Training 2Health News:SF Custom Chiropractic Celebrates National Relaxation Day and the Benefits of Massage Therapy for the Month of August 2Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2
... marketing is a missed opportunity for states to improve ... alcohol advertising laws from the Center on Alcohol Marketing ... of Public Health. The report examines the ... different best practices to reduce youth exposure to alcohol ...
... of an important clinical trial on age-related macular degeneration ... (or CATT), were published in the journal Ophthalmology ... Avastin (bevacizumab) and Lucentis (ranibizumab), commonly used to treat ... maintaining vision. In this clinical trial ...
... -- A management plan to gather, assess and respond to ... approved until they are no longer on the market is ... an Institute of Medicine report released Tuesday. The U.S. ... trial evidence that their benefits outweigh their risks. However, the ...
... MONDAY, April 30 (HealthDay News) -- A new analysis ... says those with a family history of breast cancer or ... The benefits of getting a mammogram every two years ... increased risk for developing breast cancer, according to the U.S. ...
... 1 (HealthDay News) -- Taser guns used by law enforcement ... according to a new study. Tasers, which are widely ... countries, are designed to stun suspects by delivering a 50,000-volt ... analyzed the cases of eight healthy men, ages 16 to ...
... for ordering chest CT examinations translates into positive examinations ... The study, conducted at Massachusetts General Hospital in Boston, ... of a decision support system, found that 76% of ... , "Rising concerns about radiation risks, imaging growth and ...
Cached Medicine News:Health News:Majority of states fail to address youth exposure to alcohol marketing 2Health News:Interpreting the Avastin-Lucentis study for persons with macular degeneration 2Health News:Interpreting the Avastin-Lucentis study for persons with macular degeneration 3Health News:Better Ways Needed to Track Drug Safety: Report 2Health News:Better Ways Needed to Track Drug Safety: Report 3Health News:Here Are the Women Who Need Mammograms in Their 40s: Study 2Health News:Here Are the Women Who Need Mammograms in Their 40s: Study 3
Smartepil II is a laser particularly indicated for hair-removal where it has proved to be a valid instrument, even in the treatment of darker phototypes and telangiectasias of the face and legs....
... Tri-Active is the result of ... the combination of three different methods ... to your skin. This treatment is ... of cellulite through the combined action ...
... is a CO2 laser system with ... Its functions in continuous and super-pulsed ... extreme laser intervention delicacy. Excellent as ... it comes with a large LCD ...
... professional digital imaging system for ophthalmology and ... to acquire, analyze, and store your patient ... use the most are,available right on the ... easily. This high-resolution system supports images captured ...
Medicine Products: